BioSpace News Archive

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.

Aptinyx Inc. today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Medexus Pharmaceuticals Inc. is pleased to announce that it will be participating in the 34th Annual Roth Conference from March 13 to 15, 2022.

Ayala Pharmaceuticals, Inc. today announced that it will present at the 32nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 for the treatment of soft tissue sarcoma.

PDS Biotechnology Corporation announced the Company will release financial results for the three- and twelve-month periods ended December 31, 2021, on Wednesday, March 23, 2022, before the market opens.

Mustang Bio, Inc. announced that an abstract reporting on Phase 1 trials being conducted at the UAB and City of Hope of Mustang Bio’s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma, has been selected as a late-breaking poster presentation at the AACR Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana.

Soleno Therapeutics, Inc. announced that Running for Research - Prader-Willi Syndrome, an organization committed to raising private donations in support of advancing the science around Prader-Willi syndrome, will fund an investigator-sponsored clinical study to evaluate Diazoxide Choline Extended-Release tablets in patients with early phase PWS.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational research data of enoblituzumab (also known as TJ271) and preclinical data of TJ-C64B will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego.